Print PDF

Sheppard Mullin Advises Unicycive Therapeutics in $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb®


The firm is representing Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, in its $130 million private placement.

The funding is being led by Vivo Capital with participation from RA Capital, BVF Partners, Logos Capital, and is supported by existing investors Nantahala Capital Partners and Rosalind Advisors Inc.

The deal was led by Jeff Fessler, co-leader of Sheppard Mullin’s Life Sciences Industry Team and associate Seth Lemings.

Click here to read the press release.

Practice Areas


Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.